What is Zacks Research's Estimate for Plexus Q1 Earnings?

Key Points

• Zacks Research has lowered its Q1 2026 earnings per share estimate for Plexus Corp. to $1.56, down from a previous estimate of $1.60, while the full-year earnings estimate stands at $5.90 per share.
• Plexus reported a Q2 earnings per share of $1.90, exceeding analyst expectations of $1.71, alongside a revenue of $1.02 billion.
$152.00, as analysts continue to show confidence in Plexus despite recent adjustments to earnings estimates.

Plexus Corp. (NASDAQ:PLXS - Free Report) - Equities research analysts at Zacks Research dropped their Q1 2026 earnings estimates for shares of Plexus in a report issued on Wednesday, August 6th. Zacks Research analyst V. Doshi now expects that the technology company will post earnings per share of $1.56 for the quarter, down from their prior estimate of $1.60. The consensus estimate for Plexus' current full-year earnings is $5.90 per share. Zacks Research also issued estimates for Plexus' FY2026 earnings at $6.42 EPS.

Plexus (NASDAQ:PLXS - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The technology company reported $1.90 EPS for the quarter, topping analysts' consensus estimates of $1.71 by $0.19. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. Plexus had a net margin of 4.04% and a return on equity of 12.33%. The firm's revenue for the quarter was up 6.0% compared to the same quarter last year. During the same period last year, the firm earned $1.45 EPS.

A number of other brokerages also recently weighed in on PLXS. Needham & Company LLC dropped their target price on shares of Plexus from $162.00 to $158.00 and set a "buy" rating for the company in a research note on Thursday, July 24th. Sidoti raised shares of Plexus from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $135.00 to $150.00 in a research note on Friday, July 25th. Benchmark reaffirmed a "buy" rating and issued a $160.00 target price on shares of Plexus in a research note on Wednesday, June 4th. Stifel Nicolaus set a $140.00 target price on shares of Plexus in a research note on Thursday, July 24th. Finally, Wall Street Zen upgraded shares of Plexus from a "buy" rating to a "strong-buy" rating in a research report on Monday, June 30th. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $152.00.

Plexus Price Performance

Shares of NASDAQ:PLXS traded up $1.78 during midday trading on Friday, reaching $129.63. 109,192 shares of the company's stock were exchanged, compared to its average volume of 230,207. Plexus has a 12 month low of $103.43 and a 12 month high of $172.89. The firm has a market capitalization of $3.50 billion, a PE ratio of 22.08 and a beta of 0.80. The company's 50 day simple moving average is $132.61 and its two-hundred day simple moving average is $130.77. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.74 and a current ratio of 1.58.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of PLXS. Aquatic Capital Management LLC grew its holdings in Plexus by 134.0% during the fourth quarter. Aquatic Capital Management LLC now owns 234 shares of the technology company's stock valued at $37,000 after purchasing an additional 134 shares during the period. Huntington National Bank lifted its stake in Plexus by 41.5% in the second quarter. Huntington National Bank now owns 324 shares of the technology company's stock valued at $44,000 after buying an additional 95 shares in the last quarter. Versant Capital Management Inc lifted its stake in Plexus by 1,000.0% in the first quarter. Versant Capital Management Inc now owns 473 shares of the technology company's stock valued at $61,000 after buying an additional 430 shares in the last quarter. TD Private Client Wealth LLC lifted its stake in Plexus by 185.6% in the first quarter. TD Private Client Wealth LLC now owns 514 shares of the technology company's stock valued at $66,000 after buying an additional 334 shares in the last quarter. Finally, Banque Transatlantique SA bought a new position in Plexus in the first quarter valued at approximately $71,000. Institutional investors and hedge funds own 94.45% of the company's stock.

Insider Activity

In related news, CAO Angelo Michael Ninivaggi, Jr. sold 2,058 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $132.22, for a total transaction of $272,108.76. Following the completion of the transaction, the chief accounting officer owned 26,133 shares in the company, valued at approximately $3,455,305.26. The trade was a 7.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Todd P. Kelsey sold 2,000 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $131.68, for a total transaction of $263,360.00. Following the transaction, the chief executive officer owned 76,714 shares of the company's stock, valued at approximately $10,101,699.52. This represents a 2.54% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,710 shares of company stock valued at $2,054,722. 1.76% of the stock is currently owned by company insiders.

Plexus Company Profile

Plexus Corp. provides electronic manufacturing services in the United States and internationally. It offers design, develop, supply chain, new product introduction, and manufacturing solutions, as well as sustaining services to companies in the healthcare/life sciences, industrial/commercial, aerospace/defense, and communications market sectors.